(XTNT) Xtant Medical Holdings - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98420P3082
XTNT: Bone Grafts, Spinal Fixation, Orthopedic Implants, Surgical Instruments
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) specializes in developing and distributing innovative regenerative medicine products and medical devices, primarily serving orthopedic and neurological surgeons. Their product portfolio includes OsteoSponge, a natural scaffold for bone growth, and OsteoSelect DBM Putty, designed for versatility in surgical applications. They also offer OsteoSelect PLUS DBM Putty, which ensures patient safety through validated sterilization. Additionally, Xtant provides 3Demin allografts for enhanced bone conductivity and osteoinductive potential, OsteoFactor for retained growth factors, and OsteoVive Plus, a growth factor-enriched bone matrix. Their nanOss product line includes hydroxyapatite and bioscaffold solutions for advanced bone repair.
The company is also a key player in allografts, offering sports allografts for ligament and meniscal repairs, milled spinal allografts for customized applications, and traditional allografts for various surgical specialties. Their spinal fixation systems include Certex, Spider, and Streamline OCT, providing solutions for cervical and lumbar spine needs. Xtants portfolio extends to minimally invasive systems like Xpress and Fortex, as well as sacroiliac joint fusion with Silex. They also offer integrated fusion systems such as Irix-C and Irix-A, and devices like Coflex for spinal stenosis and CoFix for spinal pain management.
Headquartered in Belgrade, Montana, Xtant Medical is a significant name in the orthopedic and spinal markets, focusing on both regenerative and structural solutions. Their comprehensive product range underscores their commitment to innovation in surgical care.
3-Month Forecast: Based on current technical and fundamental data, XTNT stock shows a sideways trend with potential volatility. Support is at $0.45 and resistance at $0.55. Breaking above resistance could target $0.65, while a drop below support may lead to $0.35. Volume remains stable without strong accumulation or distribution signals. The negative RoE and moderate ATR of 0.07 suggest cautious market sentiment, advising careful monitoring of price movements and volume trends.
Additional Sources for XTNT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
XTNT Stock Overview
| Market Cap in USD | 64m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 2015-10-19 |
XTNT Stock Ratings
| Growth 5y | -50.6% |
| Fundamental | -35.2% |
| Dividend | 0.0% |
| Rel. Strength Industry | -56.9 |
| Analysts | 5/5 |
| Fair Price Momentum | 0.41 USD |
| Fair Price DCF | - |
XTNT Dividends
No Dividends PaidXTNT Growth Ratios
| Growth Correlation 3m | 41.1% |
| Growth Correlation 12m | -87% |
| Growth Correlation 5y | -46.6% |
| CAGR 5y | -9.61% |
| CAGR/Max DD 5y | -0.10 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -73.51 |
| Beta | 1.76 |
| Volatility | 106.79% |
| Current Volume | 3.8k |
| Average Volume 20d | 35.4k |
As of March 18, 2025, the stock is trading at USD 0.48 with a total of 3,824 shares traded.
Over the past week, the price has changed by +9.59%, over one month by -15.13%, over three months by +37.14% and over the past year by -56.36%.
Probably not. Based on ValueRay Fundamental Analyses, Xtant Medical Holdings (NYSE MKT:XTNT) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.15 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of XTNT as of March 2025 is 0.41. This means that XTNT is currently overvalued and has a potential downside of -14.58%.
Xtant Medical Holdings has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy XTNT.
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, XTNT Xtant Medical Holdings will be worth about 0.5 in March 2026. The stock is currently trading at 0.48. This means that the stock has a potential downside of -4.17%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 1.8 | 264.6% |
| Analysts Target Price | 2.3 | 368.8% |
| ValueRay Target Price | 0.5 | -4.2% |